Quadrature Capital’s Relmada Therapeutics RLMD Stock Holding History

Quadrature Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,498	Closed	-$87K	–	1982
2026 Q1	$87K	Sell	12,498 -40,946	-77%	-$194K	﹤0.01%	1239
2025 Q4	$258K	Buy	+53,444	New	+$179K	﹤0.01%	894

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrature Capital's RLMD Position: Q2 2026 in Review

Quadrature Capital sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 12,498 shares — an estimated $87K sold.

Quadrature Capital first reported a position in RLMD in Q4 2025 and held it in 2 quarters. The position peaked at $258K in Q4 2025. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Quadrature Capital reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 12,498 Relmada Therapeutics shares in Q2 2026, an estimated $87K.
Quadrature Capital first reported a position in Relmada Therapeutics in Q4 2025 and held it in 2 quarters.
Quadrature Capital's Relmada Therapeutics position peaked at $258K in Q4 2025.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.